
    
      STUDY DESIGN AND METHODOLOGY:

      This was a multicentre, randomised, double-blind, placebo- and active-controlled, four-way
      crossover study. The study consisted of 4 treatment periods in at least 16 patients with PD
      treated with standard release levodopa/carbidopa (Sinemet®). Patients were randomly assigned
      to treatment with placebo, nebicapone 75 mg, nebicapone 150 mg or entacapone 200 mg (Comtan®)
      in 4 different sequences.
    
  